Pathology and Molecular Markers


One of the key goals of the Comparative Brain Tumor Consortium (CBTC) is to establish the translational relevance of canine brain tumors as models for their human counterparts. To begin to address this highly complex and involved project, we began by investigating the histologic landscape of canine glioma and engaging a panel of expert physician and veterinary neuropathologists. The goal is to evaluate the features of canine glioma and determine how best to classify them with input from both human and veterinary perspectives, so that common ground can be established at the most basic level of tumor diagnosis.

This pathology board convened on March 20-21, 2017 to review and propose a new classification schema for canine glioma. The board consisted of 6 MD pathologists and 10 DVM pathologists, and collectively is reviewing over 200 canine cases collected from 11 different veterinary institutions. It is anticipated the CBTC will publish the new classification schema later this year.

Future efforts in this project will include review of existing and planned molecular phenotyping datasets that can be correlated back to histologic diagnosis and classification, with the ultimate goal of generating a canine glioma TCGA.

This effort was led by Drs. Jey Koehler, Andrew Miller, Ryan Miller, and Brian Porter